Handling Chemotherapy Safely: Extravasation, Exposure and Fertility
The same molecule designed to kill a tumour will kill anything it touches: the tissue of a patient's arm if it leaks from the vein, the DNA of the nurse who prepares it, the future children of the young man receiving it. Chemotherapy safety is not paperwork — it is three sharp reflexes: stop a leak the moment it starts, wear the armour every time, and counsel about fertility before the first dose, not after.
The doxorubicin is running — a bright red drip into a vein on the back of the hand. The patient shifts and mentions a burning ache spreading up the arm. The nurse looks: the skin near the cannula is puffing, tight. She pulls back on the line for a blood return and gets nothing. Two signs, one conclusion — the drug is no longer in the vein, it is in the tissue. She does not wait. She STOPS the infusion, leaves the cannula in and aspirates back what she can, elevates the arm, and calls for cold packs and the antidote dexrazoxane — because a vesicant sitting in soft tissue is a chemical burn that can eat down to tendon. Across the corridor, in a quiet room, a 24-year-old man is doing his own kind of safety step before his first cycle: banking sperm, protecting a future the treatment might take from him.
Extravasation: when the drug leaves the vein
Extravasation is the accidental leakage of an infused drug out of the vein into the surrounding tissue. Not every leak is equal. Drugs are graded by how much damage they do outside the vein. Vesicants are the dangerous class: they cause blistering, tissue necrosis and ulceration that can progress for weeks. The classic vesicants are the anthracyclines (doxorubicin, daunorubicin, epirubicin) and the vinca alkaloids (vincristine, vinblastine, vinorelbine). Irritants are milder — they cause pain, aching and inflammation along the vein, but not usually necrosis. A third group, non-vesicants, cause little local harm. Knowing which class is in the bag tells you how frightened to be when it leaks.
Recognition is the whole game, because damage is proportional to how long the drug sits in the tissue. The warning signs during an infusion: new pain or burning at the site, swelling or puffiness, redness, leaking around the cannula, a slowed drip, and — the single most useful sign — loss of blood return when you pull back on the line. A patient who says "it's starting to hurt" is giving you data, not a complaint. Treat any of these as extravasation until proven otherwise.
The first reflexes — and the drug-specific split
The universal first steps are the same for any vesicant. STOP the infusion immediately. Do NOT pull the cannula yet — leave it in and aspirate back as much drug as you can through it. Disconnect the line, elevate the limb to reduce swelling, and mark and photograph the area. Then escalate: notify the extravasation team, and involve plastic surgery early for a significant vesicant leak. What comes next splits by drug class — and getting the split wrong makes the injury worse.
For an anthracycline (doxorubicin) leak: apply COLD packs — cold vasoconstricts, localizes the drug and limits spread. The specific antidote is dexrazoxane, given IV (in a different limb) within about 6 hours and repeated over 3 days; it markedly reduces the need for surgical debridement. Note the elegant crossover: dexrazoxane is the same iron-chelating drug used as a cardioprotectant to limit anthracycline heart toxicity — one antidote, two roles. Topical dimethyl sulfoxide (DMSO) is an alternative in some protocols. Do NOT use cold for a vinca leak.
For a vinca alkaloid (vincristine, vinblastine) leak, everything flips. Apply WARM packs — warmth vasodilates and disperses the drug away from the concentrated pocket — and give hyaluronidase injected subcutaneously around the site, which breaks down tissue hyaluronic acid so the trapped drug spreads and is diluted. Cold here would concentrate the vinca and deepen the injury. This is exactly the pair students transpose under pressure: cold + antidote for anthracyclines, warm + hyaluronidase for vincas.
The best treatment for extravasation is never needing one. Give known vesicants through a secure central line (a port or PICC), not a fragile hand or wrist vein; use the largest, newest, best-flowing cannula; verify blood return before and during; and infuse vesicants by slow push into a fast-running carrier so any leak is caught early. Prevention is a protocol, not luck.
- Vesicants (anthracyclines, vinca alkaloids) cause necrosis; irritants cause inflammation only.
- Loss of blood return + new pain/swelling = extravasation until proven otherwise.
- First reflexes: STOP, don't remove the cannula, aspirate, elevate, escalate.
- Anthracycline → COLD packs + dexrazoxane antidote.
- Vinca alkaloid → WARM packs + hyaluronidase (the opposite temperature).
- Prevent it: central line for vesicants, confirm blood return, involve plastics early.
Occupational exposure: the drug is hazardous to YOU
Cytotoxic drugs do not distinguish a cancer cell from your cell. The very properties that make chemotherapy work — damaging DNA and blocking cell division — make it a hazardous drug for everyone who handles it. Many cytotoxics are mutagenic (cause genetic mutations), teratogenic (harm a developing fetus) and carcinogenic (linked to cancer) on chronic exposure. Staff can absorb them by skin contact, needlestick, inhaling aerosols during preparation, or contact with a treated patient's body fluids. The risk to any one nurse from a single dose is small, but it is cumulative over a career — which is why handling is engineered, not left to chance.
Safe handling is a chain, and every link matters. Preparation happens in a biological safety cabinet (a class II vertical-flow hood) or isolator, ideally using closed-system transfer devices (CSTDs) that prevent aerosol and liquid escape when connecting syringes and bags. Personal protective equipment means chemotherapy-rated gloves (double-gloved, changed frequently), an impervious gown, and eye and respiratory protection when splash is possible. A dedicated spill kit must be on hand and staff trained to use it. Waste — vials, tubing, gloves — goes into labelled cytotoxic (purple) waste containers, never general waste.
The hazard doesn't end when the infusion does. Cytotoxics and their active metabolites are excreted in the patient's urine, stool, vomit, sweat and blood for roughly 48 hours after a dose (longer for some agents). During that window, staff and home carers should wear gloves (and a gown if soiling is likely) when handling body fluids or soiled linen, double-flush the toilet with the lid down, and wash contaminated laundry separately. Cyclophosphamide and cisplatin are classic examples excreted largely unchanged in urine. The patient is not radioactive — but their waste is genuinely hazardous for two days.
- Cytotoxics are hazardous drugs: mutagenic, teratogenic, carcinogenic on chronic exposure.
- Prepare in a biological safety cabinet, ideally with closed-system transfer devices (CSTDs).
- PPE: chemo-rated gloves (double), impervious gown, eye/respiratory protection for splash.
- Keep a spill kit ready; dispose of drug + materials as cytotoxic waste.
- Body fluids stay hazardous ~48 h after a dose — glove up and double-flush.
Fertility and pregnancy: counsel before the first dose
Because cytotoxics target dividing cells, they hit the fast-dividing cells of the ovaries and testes hard. Many regimens — and pelvic radiotherapy — cause temporary or permanent infertility: alkylating agents such as cyclophosphamide are among the most gonadotoxic, and procarbazine is a notorious cause of infertility in regimens like those for Hodgkin lymphoma. In men, sperm counts can fall to zero; in women, treatment can trigger premature ovarian failure and early menopause. This is not a side effect to discover afterward — it is a conversation that must happen BEFORE treatment begins, while options still exist.
For a man, the standard is sperm banking (cryopreservation) before the first cycle — quick, cheap and effective, exactly what the young man in the scene was doing. For a woman, options include harvesting and freezing eggs (oocyte) or embryos, and — when there is no time to stimulate, as in an aggressive leukaemia needing treatment within days — ovarian tissue cryopreservation for later re-implantation. Referral to a fertility service should happen the moment a gonadotoxic plan is set, because egg/embryo storage needs a stimulation cycle that treatment can't wait for if it's left too late.
Two more rules close the loop. First, contraception: because cytotoxics are teratogenic, effective contraception is essential during treatment and for a period afterward (typically months, agent-dependent) for both women and men — a pregnancy conceived mid-chemo carries real risk of malformation. Second, chemotherapy in pregnancy: it is generally avoided in the first trimester, when organogenesis makes the fetus most vulnerable to teratogenic and lethal effects; some regimens can be given more safely in the second and third trimesters when a pregnancy must continue, always as a specialist, individualized decision. The link back to basic pharmacology is direct: this is teratogenicity and individual variation from the pharmacodynamics chapter, playing out at the highest stakes.
- Many cytotoxics (alkylators, procarbazine) and pelvic radiotherapy cause infertility.
- Counsel about fertility and offer preservation BEFORE the first dose.
- Preservation: sperm banking; egg/embryo freezing; ovarian tissue when time is short.
- Cytotoxics are teratogenic — effective contraception during and after treatment.
- Avoid chemotherapy in the first trimester wherever possible.
- Treating a vesicant extravasation as a minor bruise and not escalating — a leak that looks small can necrose down to tendon over days.
- Using the wrong temperature: cold on a vinca leak or warm on an anthracycline leak. Mixing them up concentrates the vesicant and deepens the injury.
- Skipping fertility counselling before a gonadotoxic regimen — once treatment starts, the window for sperm or egg banking may be gone.
- Underestimating occupational exposure — handling cytotoxics or a patient's body fluids without PPE, or dropping precautions before 48 hours have passed.
A doxorubicin (anthracycline) infusion extravasates. After stopping the infusion and aspirating, which local measure and antidote are correct?
- Extravasation: STOP, aspirate, elevate, escalate — vesicants (anthracyclines, vinca) can necrose tissue.
- Anthracycline = COLD + dexrazoxane; vinca = WARM + hyaluronidase (never swap them).
- Cytotoxics are hazardous drugs: safety cabinet, CSTDs, PPE, and 48-hour body-fluid precautions.
- Counsel fertility and offer preservation before treatment; contraception during; avoid first-trimester chemo.
- Katzung BG. Basic & Clinical Pharmacology — Cancer Chemotherapy: toxicity, vesicant injury & handling of cytotoxic agents.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antineoplastic agents: gonadal toxicity & teratogenicity.
- Polovich M, Olsen M, LeFebvre K. Chemotherapy and Biotherapy Guidelines (Oncology Nursing Society) — safe handling, PPE & extravasation management.
- European Society for Medical Oncology (ESMO) Clinical Practice Guidelines — Management of chemotherapy extravasation.
- NIOSH / USP <800> — Handling of hazardous drugs in healthcare settings.
- ASCO Fertility Preservation in Patients With Cancer — Clinical Practice Guideline.
